•  
  •  

Scholarly Commons > HCA Healthcare Journal > Vol. 2 > Iss. 4 (2021)

 

Keywords

infantile botulism; BabyBIG; botulism; neurotoxicity syndromes; intravenous immunoglobulins/therapeutic use; infant

Disciplines

Infectious Disease | Other Pharmacy and Pharmaceutical Sciences | Pediatrics

Abstract

Infantile botulism is a potentially devastating disease caused by ingestion of Clostridium botulinum spores through food products or dust particles. The toxin produced by the spores can lead to descending paralysis requiring hospitalization for supportive care which sometimes includes mechanical ventilation. Human Botulism Immune Globulin-Intravenous (BIG-IV or BabyBIG) from the Infant Botulism Treatment and Prevention Program (IBTPP) has been shown to greatly improve outcomes. A previously healthy 5-month-old infant was admitted to her regional hospital for poor feeding and lethargy. When the weakness progressed and she had trouble with protecting her airway, she was intubated and transferred to our institution. The primary diagnosis was infantile botulism and the decision was made to treat with BabyBIG. The pharmacy department was able to assist with obtaining BabyBIG, ensuring proper preparation, and coordinating the team for swift administration. In the days following the BabyBIG administration, the patient slowly started to recover her respiratory function and muscle tone. On day five of admission the patient was extubated. After transfer to the general pediatric floor the patient was given a transpyloric feeding tube and worked with gastrointestinal and nutrition services to improve oral feeding. She was discharged on day seventeen with plans to continue working with therapy and nutrition. BIG-IV can have a major impact in the recovery of infantile botulism. Pharmacists are in an optimal position to assist with coordinating the multidisciplinary team regarding its procurement, preparation, and administration.

Download

Share

COinS